AstraZeneca PLC has signed an exclusive framework agreement with China’s Shenzhen Kangtai Biological Products to supply its COVID-19 vaccine candidate in mainland China, the British pharmaceutical giant said. The two companies will also explore the possiblity of cooperation on the vaccine candidate in other markets, AstraZeneca said.

(Moneycontrol)